Isoeugenol suppression of inducible nitric oxide synthase expression is mediated by down-regulation of NF-kappaB, ERK1/2, and p38 kinase

Eur J Pharmacol. 2007 Dec 8;576(1-3):151-9. doi: 10.1016/j.ejphar.2007.07.034. Epub 2007 Jul 26.

Abstract

Isoeugenol, which is a naturally occurring o-methoxyphenol in a variety of foods and essential oils, is known to have anti-inflammatory effects, although the mechanism is not clear. In the present study, we investigated the effect of isoeugenol on NF-kappaB signaling leading to inducible nitric oxide synthase (iNOS) expression in RAW 264.7 murine macrophages stimulated with lipopolysaccharide (LPS). Isoeugenol markedly inhibited nitric oxide (NO) production in dose- and time-dependent manners. The decrease in NO production was found to correlate with a decrease in iNOS expression, as determined by Western blot analysis and real-time RT-PCR. To characterize further the inhibitory mechanisms of isoeugenol at the transcriptional level, we examined the DNA-binding and transcriptional activities of NF-kappaB. Isoeugenol inhibited NF-kappaB-dependent transcriptional activity and DNA-binding activity by decreasing the nuclear translocation of p65, which is a component of NF-kappaB. In addition, isoeugenol blocked signaling upstream of NF-kappaB activation, such as degradation of I-kappaBalpha and the phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK), in LPS-stimulated RAW 264.7 cells. The isoeugenol analogues eugenol and allylbenzene also inhibited LPS-induced NF-kappaB signaling and iNOS expression, albeit with less potency than isoeugenol. These results suggest that isoeugenol and its analogues inhibit NO production and iNOS expression in LPS-stimulated RAW 264.7 cells, and that these effects are mediated, at least in part, by blocking the phosphorylation of ERK1/2 and p38 kinase, degradation of I-kappaBalpha, and activation of NF-kappaB.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allyl Compounds / pharmacology*
  • Animals
  • Benzene Derivatives / pharmacology*
  • Cell Line
  • Cell Survival / drug effects
  • Down-Regulation
  • Eugenol / analogs & derivatives*
  • Eugenol / pharmacology*
  • Gene Expression Regulation / drug effects
  • Genes, Reporter / genetics
  • I-kappa B Proteins / metabolism
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Mice
  • Mitogen-Activated Protein Kinases / metabolism
  • NF-KappaB Inhibitor alpha
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Nitric Oxide / antagonists & inhibitors*
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type II / antagonists & inhibitors*
  • Nitric Oxide Synthase Type II / genetics
  • Nitric Oxide Synthase Type II / metabolism
  • Nitrites / metabolism
  • RNA, Messenger / metabolism

Substances

  • Allyl Compounds
  • Benzene Derivatives
  • I-kappa B Proteins
  • NF-kappa B
  • Nfkbia protein, mouse
  • Nitrites
  • RNA, Messenger
  • NF-KappaB Inhibitor alpha
  • allylbenzene
  • Nitric Oxide
  • Eugenol
  • isoeugenol
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Mitogen-Activated Protein Kinases